BETAMETHASONE DIHYDROGEN PHOSPHATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H30FO8P
Molecular Weight	472.441
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BETAMETHASONE DIHYDROGEN PHOSPHATE

Structure Search

SMILES

[H][C@@]12C[C@H](C)[C@](O)(C(=O)COP(O)(O)=O)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=VQODGRNSFPNSQE-DVTGEIKXSA-N

InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugbank.ca/drugs/DB00443

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.Betamethasone is used for: treating certain conditions associated with decreased adrenal gland function. It is used to treat severe inflammation caused by certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 172 Target ID: CHEMBL2034 Sources: https://www.drugbank.ca/drugs/DB00443 \| https://www.ncbi.nlm.nih.gov/pubmed/12188035	Agonist 2678		1.3 nM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Asthma 241 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Primary	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961
Allergic rhinitis 100 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Primary	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961
Congenital adrenal hyperplasia 41 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Primary	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961
Ulcerative colitis 123 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Primary	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961
Lymphomas 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Palliative	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961
Acute exacerbations of multiple sclerosis 13 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/014602s059lbl.pdf	Primary	Approved 8429	CELESTONE SOLUSPAN Approved Use When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date 1961

C_max

Value	Dose	Analyte	Population
76.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
67.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
101 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/	8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
796 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
811 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
46.3 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/	8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
13.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
10.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984	6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
335 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/	8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered:	BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
36% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/	8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered:		BETAMETHASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
7.2 mg 1 times / day multiple, oral Highest studied dose Dose: 7.2 mg, 1 times / day Route: oral Route: multiple Dose: 7.2 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/014215s009s015lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/014215s009s015lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/014215s009s015lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882 OATP1B1 788 OATP1B3 706 BSEP 402 MRP2 383 MRP3 157 MRP4 204	CYP19A1 23 P-gp 1537	CYP3A5 76 CYP2A6 79 CYP1B1 51 CYP2B6 547 CYP2C8 168 CYP2C19 293 CYP3A7 15

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 739	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 1819	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNjMyIn19	no [IC50 >10 uM]
CYP2E1 970	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 1925	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNjMyIn19	no [IC50 >10 uM]
BSEP 403	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP2 475	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 207	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP4 238	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2B6 1001	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443\| https://pubmed.ncbi.nlm.nih.gov/17101742/	no
CYP1B1 67	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443 \| https://pubmed.ncbi.nlm.nih.gov/24451000/	yes
CYP2A6 739	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443 \| https://pubmed.ncbi.nlm.nih.gov/24451000/	yes
CYP2C19 1553	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443 \| https://pubmed.ncbi.nlm.nih.gov/24451000/	yes
CYP2C8 965	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443 \| https://pubmed.ncbi.nlm.nih.gov/24451000/	yes
CYP2C9 1819	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443 \| https://pubmed.ncbi.nlm.nih.gov/24451000/	yes
CYP3A4 1925	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443\| https://pubmed.ncbi.nlm.nih.gov/22673009/	yes
CYP3A5 130	inducer 1573 Sources: https://go.drugbank.com/drugs/DB00443\| https://pubmed.ncbi.nlm.nih.gov/22673009/	yes
CYP3A7 22	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/22673009/	yes
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/23571415/	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP19A1 23	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00443\| https://go.drugbank.com/articles/A182870	yes
P-gp 1537	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00443\| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw0MzAyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDYzMiJ9fQ%3D%3D	yes
CYP3A4 1737	substrate 3367 Sources: https://go.drugbank.com/drugs/DB00443\| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C303&ns=ncit&type=relationship&key=1874461855&b=1&n=0&vse=null \| https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/762/original/1.pdf?1532386869	yes	yes (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Sources: https://go.drugbank.com/drugs/DB00443\| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C303&ns=ncit&type=relationship&key=1874461855&b=1&n=0&vse=null \| https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/762/original/1.pdf?1532386869

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNjMyIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3077	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3077
ChemicalBook	CB7392335	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7392335
MolPort	MolPort-003-845-025	https://www.molport.com/shop/molecule-link/MolPort-003-845-025
Selleck Chemicals	Betamethasone-(Celestone)	http://www.selleckchem.com/products/Betamethasone-(Celestone).html
ZINC	ZINC000003876136	http://zinc15.docking.org/substances/ZINC000003876136
eMolecules	31224942	https://www.emolecules.com/cgi-bin/more?vid=31224942
eMolecules	535310	https://www.emolecules.com/cgi-bin/more?vid=535310

PubMed

Title	Date	PubMed
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.	2001	11586014
Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis.	2001	11517852
[Rupture of the Achilles tendon after local steroid injection. Case reports and consequences for treatment].	2001	11515194
Effects of endogenous and exogenous glucocorticoids on liver differentiation.	2001	11396842
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.	2001 Apr	11501509
[Analysis of selected parameters of maternal and fetal status during stimulation of fetal lung maturation].	2001 Apr	11444174
[Dyshidrosis and acral purpura during polymorphic dermatitis in pregnancy: 2 cases].	2001 Apr	11395652
A topical steroid without an antibiotic cures external otitis efficiently: a study in an animal model.	2001 Aug	11583468
Severe oral manifestations of chronic graft-vs.-host disease.	2001 Aug	11575020
The delivery of topical nasal sprays and drops to the middle meatus: a semiquantitative analysis.	2001 Aug	11559340
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required.	2001 Aug	11535143
Infantile acute hemorrhagic edema of the skin.	2001 Aug	11534914
Multiple courses of antenatal betamethasone and cognitive development of mice offspring.	2001 Aug	11531154
Painless thyroiditis induced by the cessation of betamethasone.	2001 Aug	11518115
Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity.	2001 Aug	11499541
Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia.	2001 Aug	11488713
Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep.	2001 Aug	11470378
Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp.	2001 Jan	11451340
Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid.	2001 Jan	11451337
Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis.	2001 Jan	11451336
Systemic ketoconazole for yeast allergic patients with atopic dermatitis.	2001 Jan	11451319
Severe vulvovaginitis associated with intravaginal nystatin therapy.	2001 Jul	11483943
The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep.	2001 Jul	11483927
An evidence-based assessment of occlusal adjustment as a treatment for temporomandibular disorders.	2001 Jul	11458263
The effect of betamethasone versus dexamethasone on fetal biophysical parameters.	2001 Jul	11435009
Nonoperative treatment of an interosseous ganglion cyst.	2001 Jul	11421523
Valsalva retinopathy-like hemorrhage associated with combined trabeculotomy-trabeculectomy in a patient with developmental glaucoma.	2001 Jul-Aug	11475401
Tocolytic magnesium sulfate toxicity and unexpected neonatal death.	2001 Jun	11533846
Deleterious effects of local corticosteroid injections on the Achilles tendon of rats.	2001 Jun	11482466
Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops.	2001 Jun	11437848
Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity.	2001 Jun	11411563
A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.	2001 Jun	11408849
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids).	2001 Jun	11407316
Treatment of de Quervain's disease:role of conservative management.	2001 Jun	11386780
Indomethacin tocolysis and intraventricular hemorrhage.	2001 Jun	11384697
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids.	2001 Mar	11405508
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.	2001 May	11448047
[Pemphigoid gestationis: treatment by topical class I corticosteroid].	2001 May	11427799
Dermatitis during radiation for vulvar carcinoma: prevention and treatment with granulocyte-macrophage colony-stimulating factor impregnated gauze.	2001 May-Jun	11472614
Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma.	2001 May-Jun	11420590
Lumbar facet joint synovial cyst: percutaneous treatment with steroid injections and distention--clinical and imaging follow-up in 12 patients.	2001 Oct	11568337
Use of antenatal steroids to counteract the negative effects of tracheal occlusion in the fetal lamb model.	2001 Oct	11568293
Antenatal corticosteroids-too much of a good thing?	2001 Oct 3	11585487
Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial.	2001 Oct 3	11585480
Growth and development of children to 4 years of age after repeated antenatal steroid administration.	2001 Sep	11585078
Repeated antenatal corticosteroid treatments. Do they reduce neonatal morbidity?	2001 Sep	11584477
Effects of antiinflammatory drugs on migration of the rabbit corneal epithelium.	2001 Sep	11566537
Multiple courses of antenatal steroids: risks and benefits.	2001 Sep	11530136
Fetal monkey surfactants after intra-amniotic or maternal administration of betamethasone and thyroid hormone.	2001 Sep	11530131
Treatment of childhood phimosis with a moderately potent topical steroid.	2001 Sep	11527265

Patents

Sample Use Guides

In Vivo Use Guide

The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended.In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day).

Route of Administration: Parenteral

In Vitro Use Guide

Betamethasone (10(-6)M) significantly reduced both pH 6-induced bronchial response and CGRP-like immunoreactivity overflow in guinea-pig isolated perfused lung.

Name

Type

Language

BETAMETHASONE DIHYDROGEN PHOSPHATE

Common Name

English

BETAMETHASONE PHOSPHATE

Common Name

English

BETAMETHASONE 21-(DIHYDROGEN PHOSPHATE)

Common Name

English

BETAMETHASONE PHOSPHATE [WHO-IP]

Common Name

English

DEXAMETHASONE SODIUM PHOSPHATE IMPURITY B [EP IMPURITY]

Common Name

English

BETAMETHASONE 21-PHOSPHATE

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-(PHOSPHONOOXY)-, (11.BETA.,16.BETA.)-

Systematic Name

English

IMPURITY B [WHO-IP]

Common Name

English

Betamethasone phosphate [WHO-DD]

Common Name

English

9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-(PHOSPHATE)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521